These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16373000)

  • 1. Current situation in the development of a preventive HIV vaccine.
    Alcamí J; Joseph Munné J; Muñoz-Fernández MA; Esteban M
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():5-24. PubMed ID: 16373000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
    Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
    J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards an HIV-1 vaccine: lessons from studies in macaque models.
    Hulskotte EG; Geretti AM; Osterhaus AD
    Vaccine; 1998; 16(9-10):904-15. PubMed ID: 9682336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines that stimulate T cell immunity to HIV-1: the next step.
    McMichael AJ; Koff WC
    Nat Immunol; 2014 Apr; 15(4):319-22. PubMed ID: 24646598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
    O'Connor D; Allen T; Watkins DI
    Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Amara RR; Villinger F; Altman JD; Lydy SL; O'Neil SP; Staprans SI; Montefiori DC; Xu Y; Herndon JG; Wyatt LS; Candido MA; Kozyr NL; Earl PL; Smith JM; Ma HL; Grimm BD; Hulsey ML; Miller J; McClure HM; McNicholl JM; Moss B; Robinson HL
    Science; 2001 Apr; 292(5514):69-74. PubMed ID: 11393868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do we not have an HIV vaccine and how can we make one?
    Burton DR; Moore JP
    Nat Med; 1998 May; 4(5 Suppl):495-8. PubMed ID: 9585194
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
    Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA gene vaccination for HIV.
    Kim JJ; Weiner DB
    Springer Semin Immunopathol; 1997; 19(2):175-94. PubMed ID: 9406345
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
    Munson P; Liu Y; Bratt D; Fuller JT; Hu X; Pavlakis GN; Felber BK; Mullins JI; Fuller DH
    Hum Vaccin Immunother; 2018 Jul; 14(7):1820-1831. PubMed ID: 29648490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination for HIV-1 and SIV.
    Barouch DH; Letvin NL
    Intervirology; 2000; 43(4-6):282-7. PubMed ID: 11251383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and strategies for AIDS vaccine development.
    Oxford JS; Frezza P; Race E
    Vaccine; 1993; 11(6):612-4. PubMed ID: 8100664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a vaccine for the prevention of AIDS, a critical appraisal.
    Karzon DT; Bolognesi DP; Koff WC
    Vaccine; 1992; 10(14):1039-52. PubMed ID: 1281948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis].
    Vieillard V; Debré P
    Biol Aujourdhui; 2015; 209(2):161-6. PubMed ID: 26514385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV vaccine development: lessons from the past and promise for the future.
    Spearman P
    Curr HIV Res; 2003 Jan; 1(1):101-20. PubMed ID: 15043215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.